Genome wide association studies (GWAS) of ten different cancers have identified pleiotropic cancer predisposition loci across a region of chromosome 5p15.33 that includes the TERT and CLPTM1L genes. Of these, susceptibility alleles for pancreatic cancer have mapped to the CLPTM1L gene, thus prompting an investigation of the function of CLPTM1L in the pancreas. Immunofluorescence analysis indicated that CLPTM1L localized to the endoplasmic reticulum (ER) where it is likely embedded in the membrane, in accord with multiple predicted trans-membrane domains. Overexpression of CLPTM1L enhanced growth of pancreatic cancer cells in vitro (1.3-1.5 fold, P DAY7 <0.003) and in vivo (3.46 fold, P DAY68 =0.039), suggesting a role in tumor growth; this effect was abrogated by deletion of two hydrophilic domains. Affinity purification followed by mass-spectrometry identified an interaction between CLPTM1L and non-muscle myosin II (NMM-II), a protein involved in maintaining cell shape, migration, and cytokinesis. The two proteins co-localized in the cytoplasm and, after treatment with a DNA damaging agent, at the centrosomes. Overexpression of CLPTM1L and depletion of NMM-II induced aneuploidy, indicating that CLPTM1L may interfere with normal NMM-II function in regulating cytokinesis. Immunohistochemical analysis revealed enhanced staining of CLPTM1L in human pancreatic ductal adenocarcinoma (n=378) as compared to normal pancreatic tissue samples (n=17) (P=1.7x10 -4 ). Our results suggest that CLPTM1L functions as a growth promoting gene in the pancreas and that overexpression may lead to an abrogation of normal cytokinesis, indicating that it should be considered as a plausible candidate gene that could explain the effect of pancreatic cancer susceptibility alleles on chr5p15.33.
Introduction
Risk variants in the TERT-CLPTM1L gene region on chromosome 5p15.33 have been reported in genome wide association studies (GWAS) for ten cancer types including bladder, breast, glioma, lung, melanoma, non-melanoma skin cancer, ovarian, pancreas, prostate and testicular germ cell cancer (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . The TERT gene encodes the catalytic subunit of the telomerase reverse transcriptase complex known for its role in maintaining telomere ends and the increased telomerase activity often seen in human cancers (14) . The CLPTM1L gene encodes the cleft lip and palate associated transmembrane 1-like protein (CLPTM1L) and was originally identified in a screen for genes conferring resistance to cisplatin in ovarian cancer cells (15) . When overexpressed in ovarian cancer cell lines, CLPTM1L induced apoptosis in cisplatin sensitive cells, giving rise to its original name: Cisplatin resistance-related protein (CRR9) (15) .
CLPTM1L was later shown to protect lung cancer cells from apoptosis after treatment with DNA damaging agents via Bcl-xL (16) .
Gain of chromosome 5p is one of the most recurrent chromosomal abnormalities in human cancers (17) . Although most commonly seen in thyroid, lung and cervical cancer, 5p gain is also frequent in other cancers including gastric, ovarian, colorectal, hepatocellular, esophageal, bladder, and pancreatic adenocarcinoma (17) (18) (19) . The most common event in early stages of nonsmall cell lung cancer (NSCLC) is gain at 5p15.33 involving both TERT (78%) and CLPTM1L (53%) (20) . However, a recent study of cervical cancer noted that CLPTM1L, but not TERT, was among the multiple genes on 5p (33%) that were both amplified and overexpressed (21, 22) .
The most significant GWAS risk variants on 5p15.33 for pancreatic cancer lie in intron 13 of the CLPTM1L gene and are located ~27 kb from the transcriptional start of TERT (11) . Author Manuscript Published OnlineFirst on March 19, 2014 ; DOI: 10.1158/0008-5472.CAN- cancer risk allele, CLPTM1L should be considered a potential target gene. Thus, to explore a possible function for CLPTM1L in pancreatic cancer, we examined its role in growth control in vitro and in vivo, and searched for interacting proteins that could provide clues to its function.
Material and Methods

Cell lines and antibodies
The human embryonic kidney cell line HEK293T, human pancreatic cancer cell line PANC-1, and mouse kidney cell line IMCD3 (all from ATCC) were maintained in Dulbecco's modified Eagle's medium (DMEM, Mediatech Inc, Herndon, VA) supplemented with 10% fetal bovine serum (Life Technologies, Grand Island, NY).
Commercial antibodies used included those for endogenous CLPTM1L (HPA014791, Sigma, St. Louis, MO), FLAG-tagged CLPTM1L (M2 F1804, Sigma), the endoplasmic reticulum (ER) marker Calnexin, (C4731, Sigma), a mitochondrial marker (MTC02, ab3298, Abcam Cambridge, MA), the centrosome marker gamma-tubulin (T5192, Sigma), the Golgi marker GM130 (G7295, Sigma), alpha-tubulin (ab7291, Abcam) and Myosin-9/MYH10 (sc-33729, Santa Cruz Biotechnology, Santa Cruz , California). Secondary antibodies were Alexa Fluor 594
Full-length human CLPTM1L cDNA (Invitrogen, Ultimate TM ORF Clone ID: IOH13343) was cloned into pDest-737 (a Gateway adapted version of Sigma's p3xFLAG-CMV10) using the Gateway system (Invitrogen). Three constructs were generated from the full-length human CLPTM1L cDNA (RefSeq NM_030782.3) and verified by Sanger sequencing: WT CLPTM1L
(full-length CLPTM1L), CLPTM1L-ΔLoop (missing amino acids (aa) 36-280 between transmembrane domains 1 and 2) and CLPTM1L-ΔCterm (lacking aa 455-538). The designed constructs include 3 tandem FLAG tags at the amino terminus of CLPTM1L. A fourth construct contained a FLAG tag at the C-terminus of CLPTM1L, to compare the effect of FLAG tags on the N-or C-termini on growth rates in vitro. Prediction of the topology of WT CLPTM1L was assessed using: TMHMM v.2.0, TMPred and TopPred2 (23) (24) (25) (26) .
In vitro and in vivo growth assays
Cell proliferation was measured in vitro by seeding PANC-1 stably expressing CLPTM1L
(full-length or deletion mutants) at 3x10 3 cells per well in 96-well plates. Time points were taken every two days (days 1, 3, 5 and 7) and cell growth assessed using the WST-1 reagent (Roche purchased from Thermo Scientific Dharmacon. Cell proliferation experiments were performed 48 hrs after transfection with 100 nM siRNA. The efficiency of CLPTM1L knock-down was assessed by isolating RNA from PANC-1 cells, using the mirVana RNA kit (ABI). Briefly, 1 μg RNA (RIN scores >9.0) was reverse transcribed using Superscript III reverse transcriptase (Invitrogen). RT-qPCR was performed on a 7900HT system (ABI) using TaqMan gene expression assays for CLPTM1L (Hs00363947_m1) and B2M (Hs00187842_m1) from Life Technologies. Each reaction was run in quadruplicate and analyzed according to the ǻǻCt method using B2M as the housekeeping gene.
Tumor growth was measured in vivo using a xenograft mouse model. Female nude mice (8-10 weeks old) were purchased from the Animal Production Area, NCI, Frederick, MD, and housed in a pathogen free environment. Briefly, 10 6 PANC-1 cells, stably transfected with different CLPTM1L constructs or the vector control, were injected subcutaneously into the flank of each mouse. Tumor size was measured by a caliper three times a week for up to 77 days using the formula of length x width x width/2 to estimate tumor volumes in mm 3 constructs expressing WT CLPTM1L with FLAG tags at either end, the CLPTM1L constructs tagged on the N-terminus were chosen for further work. Final results were pooled from 3 independent experiments: two that were performed with PANC1-vo (empty vector) and PANC1-CLPTM1L cells, and a third experiment that used PANC1-vo, PANC1-CLPTM1L, PANC1-CLPTM1L-ΔLoop and PANC1-CLPTM1L-ΔCterm cells. The difference in growth rates was analyzed by comparing tumor volumes at day 68 using the Mann-Whitney U test. Animal care and experimental procedures were approved by the NIH Animal Care and User Committees (PB-047 M1 to Dr. Javed Khan).
Affinity purification of protein complexes, tryptic digestion and fractionation
HEK293T cells were grown to ~60% confluency and transfected with 3xFLAG-tagged WT CLPTM1L (experimental analysis) or vector only (control) in a complex of polymer PEI (Polysciences Inc, Warrington, PA) and DNA at a ratio of 5:2. After 48 hrs, cells were harvested on ice in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 0.1% SDS, 0.5% Sodium Deoxycholate, 1.0% NP-40) with 1x protease inhibitor cocktail (Roche, Nutley, NJ). Lysates were incubated with 25ȝL of anti-FLAG M2 agarose (Sigma) for 2 hours followed by washing and elution via a 3x-FLAG peptide as previously described (Das PMID: 20968308) . The eluates were subjected to overnight digestion with trypsin (1 μg) at 37 o C followed by lyophilization, reconstitution and fractionation using strong cation exchange (SCX) liquid chromatography (LC) and mass spectrometry analysis as previously described (27) . Proteomics Data Analysis was performed as previously described (27) . HEK293T cells were transfected with 3xFLAG-tagged WT CLPTM1L expression plasmids or the vector control only, and collected 48 hours after transfection. PANC-1 cells stably expressing WT CLPTM1L, CLPTM1L-ΔLoop or CLPTM1L-ΔCterm were cultured to a confluence of ~80%. Cells were washed with ice cold PBS and harvested in lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 0.5mM EDTA, 1.0% NP-40, with 1x protease inhibitor cocktail).
Validation of CLPTM1L-MYH9 interaction by co-IP
Immunoprecipitation (IP) of FLAG-tagged CLPTM1L was performed by incubating the supernatant with anti-FLAG M2 agarose for 2 hours at 4°C. Affinity complexes were washed and interacting complexes released from FLAG beads by boiling in 2xLDS sample buffer (Invitrogen) and resolved on a 3-8% Tris-Acetate gel (Invitrogen). Samples were subjected to western analysis using antibodies to FLAG M2, Myosin 9/10 and beta-actin followed by appropriate secondary mouse or rabbit antibodies (Thermo Scientific, Rockford, MO) before detection of the signal with ECL (Thermo Scientific).
Cell cycle and DNA content analysis
The effect of CLPTM1L and MYH9 on cell cycle progression was studied by flow cytometric analysis of DNA content and BrdU incorporation using the FITC BrdU Flow kit Dharmacon. Twenty-four hours after transfection with 100 nM siRNA, the media was replaced with fresh complete media. Assays were performed 48 hours after transfection.
Efficiency of MYH9 knock-down was assessed by isolating RNA from PANC-1 cells, using the mirVana RNA kit (ABI). Briefly, 1 μg RNA (RIN scores >9.0) from cell lines was reverse transcribed using Superscript III reverse transcriptase (Invitrogen). RT-qPCR was performed on a 7900HT system (ABI) using TaqMan gene expression assays for MYH9 (Hs00159522_ml) and B2M (Hs00187842_m1) from Life Technologies. Each reaction was run in quadruplicate and analyzed according to the ǻǻCt method using B2M as the housekeeping gene.
Immunofluorescence (IF) and in situ Proximity Ligation Assay (DPLA)
To visualize the subcellular localization of the endogenous or FLAG-tagged CLPTM1L proteins, cells were grown on glass coverslips, fixed with 4% paraformaldehyde (PFA) or 100% methanol and stained with antibodies against endogenous CLPTM1L (1:500), FLAG-tagged CLPTM1L (1:500), Calnexin (1:500), mitochondrial marker (1:500), GM130 (1:500), alphatubulin (1:1000) and gamma-tubulin (1:1000) followed by visualization by confocal microscopy (SEER) registries (29, 30) . The TMAs from the Mayo Clinic (four TMAs were used: PDAC (pancreatic ductal adenocarcinoma) TMA1 (n=111), PDAC GEM (gemcitabine) (n=156), PanIN (pancreatic intraepithelial neoplasia) TMA (n=13) and pancreatic islet cell tumors (Islet cell TMAs) (n=41) along with 3 cores of tissues from normal pancreas that could be evaluated for CLPTM1L expression. The SEER TMA contained 14 cores from normal pancreas (adjacent to tumor) in addition to PDAC (n=111) and islet cell tumors (n=7).
Immunohistochemistry for CLPTM1L was performed with a rabbit polyclonal antibody (HPA014791, Sigma, St. Louis, MO) at 1:1600 dilution. Briefly, slides were de-paraffinized in xylene and graded alcohols, and subject to antigen retrieval in a pressure cooker with citrate buffer (pH6) for 20 min. Endogenous enzyme activity was blocked with 3% hydrogen peroxide in methanol with an additional block in 2% non-fat milk used to reduce nonspecific reactions.
Subsequently, slides were incubated with primary antibody for 60 min at room temperature, 
Results
Subcellular localization of CLPTM1L
The protein product of the CLPTM1L gene is predicted to contain 6 transmembrane (TM) domains and two large hydrophilic domains: a loop between the first and second TM domains, and a C-terminal tail. It is highly conserved in primates and relatively well conserved in flies and nematodes (31) . We assessed the subcellular localization of endogenous CLPTM1L in pancreatic (32) . No staining was detected in the Golgi apparatus (Figure 1d) . To confirm that the ER localization of overexpressed WT FLAG-tagged CLPTM1L observed was not due to defects in polarized sorting, we transiently expressed CLPTM1L in mouse kidney IMCD3 epithelial cells and observed co-localization with the ERmarker calnexin (Supplemental Figure 1) . Two of the three programs used to predict the topology of CLPTM1L indicated that the N-and C-termini of the protein protrude into the lumen of the ER and other organelles it resides in (TMPred and TMHMM) but one (TopPred) predicted an opposite topology with both ends on the cytoplasmic face of the ER (23 loop structure between TM1 and TM2 is expected to be on the opposite side of the membrane as compared to the N-and C-termini.
CLPTM1L overexpression enhances cell proliferation in vitro and in vivo
To investigate if CLPTM1L influenced growth, we overexpressed full-length or mutant 
WT CLPTM1L interacts with non-muscle myosin II (NMM-II) in pancreatic cancer cells
To investigate further the molecular function of the CLPTM1L protein, we searched for interacting proteins using affinity purification, followed by liquid chromatography and mass spectrometry (LC MS/MS) analysis. Since CLPTM1L is predicted to be highly hydrophobic, we performed the screen in RIPA buffer to facilitate solubilization of membrane-associated proteins.
The most frequently observed peptides (Supplemental Table 1 Interestingly, the ER marker calnexin was identified as a potential CLPTM1L interacting protein (Supplemental Table 1 ), consistent with the observed ER localization shown above using immunofluorescence analysis.
The interaction between CLPTM1L and non-muscle myosin II (NMM-II) was confirmed by co-immunoprecipitation in both PANC-1 (Figure 4a ) and 293T cells (Figure 4b ). An interaction between the two CLPTM1L deletion mutants and non-muscle myosin II was absent or very low (Figure 4a) , indicating that the loop and C-terminal domains are required for the interaction between the two proteins. To assess where in the cells CLPTM1L and non-muscle myosin II interact, we performed co-localization experiments by in situ Proximity Ligation Assay (DPLA) (Duolink) (Figure 4c ) and immunofluorescence (IF) (Figure 4d ) and confirmed the interaction.
Since CLPTM1L has been shown to protect cells from cisplatin induced apoptosis (16, 32) we treated PANC-1 stably transfected cells with 50 μM cisplatin for 0, 24 or 48 hours and observed a shift in the extent of co-localization after 48 hours of cisplatin treatment (Figure 4c) . Instead of widespread cytoplasmic co-localization for CLPTM1L and NMM-II, fewer areas of colocalization were seen after cisplatin treatment, especially after 48 hrs (lower panels in Figure   4c ). These were often as few as one or two prominent dots per cell, located close to the nucleus (lower right panel in Figure 4c ). This pattern was confirmed using IF, showing prominent colocalization of CLPTM1L and non-muscle myosin II after cisplatin treatment in dot-like structures with tubular projections located at the nuclear periphery (Figure 4d, right panels) . We hypothesized that these structures were centrosomes, and confirmed that both CLPTM1L and non-muscle myosin II co-localized with the centrosome marker γ-tubulin, as shown in Figure 5a for the former and in Figure 5b for the latter, indicating that the two proteins probably interact specifically at centrosomes after DNA damage induction by cisplatin. Co-localization of CLPTM1L and γ-tubulin was confirmed using IF (Figure 5c ) indicating co-localization in dotlike structures close to the nucleus consistent with a single centrosome per cell.
Overexpression of WT CLPTM1L results in increased aneuploidy
Based on the interaction with non-muscle myosin II and co-localization with γ-tubulin at the centrosome, we assessed DNA content and cell cycle progression by FACS analysis after samples indicating that CLPTM1L levels may also be increased in pancreatic endocrine tumors.
Discussion
Chromosome 5p15.33 contains a pleiotropic cancer predisposition locus identified in GWAS of at least ten cancer types (34) . Multiple independent loci, in the TERT gene or the neighboring CLPTM1L gene, have been identified in this region (1-13, 35, 36) . Some, but not all, risk loci have been associated with TERT expression or with telomere length (35, 36) . To further define the underlying biology of the susceptibility alleles on 5p15.33, we investigated the function of a plausible candidate gene, CLPTM1L, and its encoded protein, cleft lip and palate transmembrane protein 1-like protein (CLPTM1L). We observed a positive effect on tumor cell growth both in vitro and in vivo, after overexpression of full-length CLPTM1L. Deletion mutants of CLPTM1L lacking either one of the two large hydrophilic domains of this predominantly hydrophobic and presumably membrane bound protein did not induce growth in vitro or in vivo, indicating that these domains may be crucial for the growth promoting function of the protein. 
A search for interacting proteins identified non-muscle myosin heavy chain, types IIA and IIB (NMM-II, also named myosin heavy chain 9/10, MYH9 or MYH10) as protein partners. The two hydrophilic domains of CLPTM1L were required for this interaction. MYH9 and MYH10 are heavy chain subunits of Myosin, a hexameric protein containing 2 heavy chains, 2 light chains and 2 regulatory chain subunits, and are important for maintaining cell shape, migration and secretion (37) (38) (39) . In addition, NMM-II plays a role in cytokinesis where it, in concert with actin and furrow components, drives the contraction needed for cytokinesis, the final step in cell division (33) . A well-known effect of blocking the expression or function of NMM-II in model organisms is a defect in cytokinesis that leads to the formation of multinucleate cells (40) (41) (42) . In nuclear membrane, which is absorbed into the ER during mitosis (44) , CLPTM1L may reside in the outer nuclear membrane (as per punctate staining pattern in Figure 1a ) and interact with centrosome proteins during cell division. It is also possible that the interaction between the two proteins in the ER and other subcellular organelles has additional functional consequences that may influence cell growth, apoptosis or other cellular activities. CLPTM1L has recently been shown to be overexpressed in lung cancer where it protects cells from apoptosis after treatment with DNA damaging agents via Bcl-xL, indicating a negative role on mitochondrial apoptotic pathways (16, 32) .
In a recent proteomics screen of the human autophagy network, CLPTM1L was shown to bind PIK3C3 (Phosphatidylinositol 3-kinase catalytic subunit type 3), indicating a possible role in autophagy (45) . Although PIK3C3 plays a central role in autophagy, it is also important for vesicle trafficking, receptor signaling and cytokinesis. Depletion of PIK3C3 in mammalian cells leads to an arrest of cytokinesis and an increased number of multinucleate cells (46) . Interestingly, in the autophagy screen, both CLPTM1L and MYH9 were also listed as interacting proteins for CLN3 (45) , a transmembrane vesicle trafficking protein that regulates cytokinesis in yeast (47) and is mutated in Batten disease (48) .
Immunohistochemical analysis showed that a substantial number of pancreatic cancers have higher levels of the CLPTM1L protein than normal pancreatic tissues, approximately 46% (range 5%-81%) of pancreatic adenocarcinomas and 92% (range 43%-100%) of islet cell tumors, indicating a possible role in carcinogenesis in both the exocrine and endocrine pancreas. A possible limitation of our study is that we have a substantially larger number of pancreatic cancers (PDAC, n=378) compared to normal samples (n=17). Thus, our findings would benefit from additional validation studies.
In summary, our results show that CLPTM1L promotes growth of pancreatic cancer cells in vitro and in vivo and that its function, at least in part, may be through abrogation of cell division.
We have shown that CLPTM1L interacts with NMM-II, and that the two proteins have opposing effects on aneuploidy. Since NMM-II is required for cytokinesis, it is possible that CLPTM1L blocks this process, perhaps by interfering with processing, localization or function of NMM-II. 
